专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2009014835A2 MODIFIED TOXINS 审中-公开
标题翻译：改性毒素
公开(公告)号：WO2009014835A2
公开(公告)日：2009-01-29
申请号：PCT/US2008/067682
申请日：2008-06-20
申请人： ANGELICA THERAPEUTICS, INC. , DAVIS, Claude, Geoffrey , DATTA, Deepshikha , BAKER, Matthew, Paul , RUST, Alyson, Jane , KEEN, Simon
发明人： DAVIS, Claude, Geoffrey , DATTA, Deepshikha , BAKER, Matthew, Paul , RUST, Alyson, Jane , KEEN, Simon
IPC分类号： A61K39/02
CPC分类号： C07K14/34 , A61K38/16 , A61K39/0011 , A61K39/39 , A61K47/6415 , A61K47/642 , A61K2039/5156 , A61K2039/55533 , A61K2039/55544
摘要： The present application relates to compositions of modified toxins exhibiting reduced immunogenicity and reduced binding to vascular endothelium or vascular endothelial cells, thereby reducing the incidence of Vascular Leak Syndrome. Also provided are polypeptide toxophores from a modified diphtheria toxin, where modifications are in at least one amino acid residue of at least one T-cell epitope. Another aspect relates to a polypeptide toxophore from a modified diphtheria toxin, where modifications are in at least one amino acid residue of at least one T-cell epitope and at least one amino acid residue of at least one VLS motif of an unmodified native diphtheria toxin. Another aspect relates to a fusion protein which comprises a modified diphtheria toxin and a non-diphtheria toxin fragment that is a cell binding portion. Another aspect relates to the use of a modified diphtheria toxin for the treatment of a malignant disease or a non- malignant disease.
摘要翻译：本申请涉及具有降低的免疫原性和减少与血管内皮细胞或血管内皮细胞结合的修饰毒素的组合物，从而降低血管渗漏综合征的发生率。还提供了来自修饰的白喉毒素的多肽毒素体，其中修饰在至少一个T细胞表位的至少一个氨基酸残基中。另一方面涉及来自修饰的白喉毒素的多肽毒候球体，其中修饰在至少一个T细胞表位的至少一个氨基酸残基和未修饰的天然白喉毒素的至少一个VLS基序的至少一个氨基酸残基。另一方面涉及融合蛋白，其包含修饰的白喉毒素和作为细胞结合部分的非白喉毒素片段。另一方面涉及使用修饰的白喉毒素治疗恶性疾病或非恶性疾病。

2. 发明申请

WO2009110944A1 MODIFIED TOXINS 审中-公开
标题翻译：改性毒素
公开(公告)号：WO2009110944A1
公开(公告)日：2009-09-11
申请号：PCT/US2008/086858
申请日：2008-12-15
申请人： ANGELICA THERAPEUTICS, INC. , DAVIS, Claude, Geoffrey , DATTA, Deepshikha , BAKER, Matthew, Paul , KEEN, Simon , RUST, Alyson, Jane
发明人： DAVIS, Claude, Geoffrey , DATTA, Deepshikha , BAKER, Matthew, Paul , KEEN, Simon , RUST, Alyson, Jane
IPC分类号： A61K38/16 , A61P37/06 , A61K39/395
CPC分类号： C07K14/34 , A61K38/00 , C07K2319/035
摘要： The present application relates to compositions of modified toxins exhibiting reduced immunogenicity and reduced binding to vascular endothelium or vascular endothelial cells, thereby reducing the incidence of Vascular Leak Syndrome. Also provided are polypeptide toxophores from a modified diphtheria toxin, where modifications are in at least one amino acid residue of at least one T-cell epitope. Another aspect relates to a polypeptide toxophore from a modified diphtheria toxin, where modifications are in at least one amino acid residue of at least one T-cell epitope and at least one amino acid residue of at least one VLS motif of an unmodified native diphtheria toxin. Another aspect relates to a fusion protein which comprises a modified diphtheria toxin and a non-diphtheria toxin fragment that is a cell binding portion. Another aspect relates to the use of a modified diphtheria toxin for the treatment of a malignant disease or a non-malignant disease.
摘要翻译：本申请涉及具有降低的免疫原性和减少与血管内皮细胞或血管内皮细胞结合的修饰毒素的组合物，从而降低血管渗漏综合征的发生率。还提供了来自修饰的白喉毒素的多肽毒素体，其中修饰在至少一个T细胞表位的至少一个氨基酸残基中。另一方面涉及来自修饰的白喉毒素的多肽毒候球体，其中修饰在至少一个T细胞表位的至少一个氨基酸残基和未修饰的天然白喉毒素的至少一个VLS基序的至少一个氨基酸残基。另一方面涉及融合蛋白，其包含修饰的白喉毒素和作为细胞结合部分的非白喉毒素片段。另一方面涉及使用修饰的白喉毒素治疗恶性疾病或非恶性疾病。

3. 发明申请

WO2014150600A8 MODIFIED TOXINS 审中-公开
标题翻译：修饰的毒素
公开(公告)号：WO2014150600A8
公开(公告)日：2014-09-25
申请号：PCT/US2014/023761
申请日：2014-03-11
申请人： ANGELICA THERAPEUTICS, INC.
发明人： DAVIS, Claude, Geoffrey , DATTA, Deepshikha , BAKER, Matthew, Paul , RUST, Alyson, Jane , KEEN, Simon
IPC分类号： A61K38/16 , A61K39/02 , C07K14/195
摘要： The present application relates to compositions of modified toxins exhibiting cytotoxicity and/or reduced immunogenicity. Also provided are polypeptide toxophores from a modified diphtheria toxin, where modifications are in at least one amino acid residue of at least one T-cell epitope. Another aspect relates to a fusion protein which comprises a modified diphtheria toxin and a non-diphtheria toxin fragment that is a cell binding portion. Another aspect relates to the use of a modified diphtheria toxin for the treatment of a malignant disease or a non-malignant disease. A modified diphtheria toxin or fusion protein may be administered with one or more other agents.
摘要翻译：本申请涉及表现出细胞毒性和/或降低的免疫原性的修饰毒素的组合物。还提供了来自修饰的白喉毒素的多肽毒素，其中修饰在至少一个T细胞表位的至少一个氨基酸残基中。另一方面涉及包含修饰的白喉毒素和作为细胞结合部分的非白喉毒素片段的融合蛋白。另一方面涉及修饰的白喉毒素用于治疗恶性疾病或非恶性疾病的用途。修饰的白喉毒素或融合蛋白可以与一种或多种其他药剂一起施用。

4. 发明申请

WO2011066608A1 WATER SWELLABLE POLYMER MATERIALS 审中-公开
标题翻译：水溶性聚合物材料
公开(公告)号：WO2011066608A1
公开(公告)日：2011-06-09
申请号：PCT/AU2010/001616
申请日：2010-12-01
申请人： THE UNIVERSITY OF SYDNEY , BAKER, Matthew, Paul , DAVEY, Timothy, Warren , HAWKETT, Brian Stanley , NGUYEN, Duc Ngoc , O'BRIEN, Caitlin, Claire , SUCH, Christopher Henry
发明人： BAKER, Matthew, Paul , DAVEY, Timothy, Warren , HAWKETT, Brian Stanley , NGUYEN, Duc Ngoc , O'BRIEN, Caitlin, Claire , SUCH, Christopher Henry
IPC分类号： C09C3/10 , C09B69/10
CPC分类号： C08L13/02 , B82Y30/00 , C01P2004/04 , C01P2006/60 , C09B67/0013 , C09C1/3072 , C09C1/3676 , C09C1/46 , C09C3/10 , C09D11/00 , C09D113/02 , Y10S977/734 , Y10T428/249953 , Y10T428/2998
摘要： The invention provides a method of preparing an aqueous dispersion of polymer encapsulated particulate material, the method comprising: providing a dispersion of the particulate material in a continuous aqueous phase, the dispersion comprising RAFT agent as a stabiliser for the particulate material; and polymerising ethylenically unsaturated monomer under the control of the RAFT agent to form polymer at the surface of the dispersed particulate material, thereby providing the aqueous dispersion of polymer encapsulated particulate material; wherein polymerisation of the ethylenically unsaturated monomer comprises: (a) polymerising a monomer composition that includes ionisable ethylenically unsaturated monomer so as to form a base responsive water swellable RAFT polymer layer that encapsulates the particulate material; and (b) polymerising a monomer composition that includes non-ionisable ethylenically unsaturated monomer so as to form an extensible, water and base permeable RAFT polymer layer that encapsulates the base responsive water swellable RAFT polymer layer.
摘要翻译：本发明提供一种制备聚合物包封的颗粒材料的水分散体的方法，所述方法包括：提供颗粒材料在连续水相中的分散体，所述分散体包含RAFT剂作为颗粒材料的稳定剂; 并在RAFT试剂的控制下聚合烯属不饱和单体以在分散的颗粒材料的表面形成聚合物，由此提供聚合物包封的颗粒材料的水分散体; 其中所述烯属不饱和单体的聚合包括：（a）聚合包含可离子化烯键式不饱和单体的单体组合物，以便形成包封所述颗粒材料的碱性响应性水溶胀性RAFT聚合物层; 和（b）聚合包含不可离子化的烯属不饱和单体的单体组合物，以便形成包封碱性响应性水可溶胀RAFT聚合物层的可延伸的水和基础可渗透的RAFT聚合物层。

5. 发明申请

WO2006082406A2 HUMAN ANTIBODIES AND PROTEINS 审中-公开
标题翻译：人类抗体和蛋白质
公开(公告)号：WO2006082406A2
公开(公告)日：2006-08-10
申请号：PCT/GB2006/000355
申请日：2006-02-03
申请人： ANTITOPE LIMITED , JONES, Timothy, David , BAKER, Matthew, Paul
发明人： JONES, Timothy, David , BAKER, Matthew, Paul
IPC分类号： C07K16/00 , C07K19/00 , A61K39/395 , C07K16/32 , C07K16/28 , C07K16/42 , C07K16/24 , C07K16/46 , C07K14/18 , C07K14/415 , C07K14/815
CPC分类号： C07K16/32 , C07K14/815 , C07K16/00 , C07K16/241 , C07K16/2863 , C07K16/2896 , C07K16/4291 , C07K2317/21 , C07K2317/24 , C07K2317/55 , C07K2317/56 , C07K2317/62 , C07K2317/622 , G01N33/53
摘要： The present invention provides composite proteins, including antibodies, which show reduced immunogenicity. In particular, composite antibodies for use in humans are provided, in particular antibodies which have been modified to remove one or more T-cell epitopes. Methods for generating such proteins are also provided.
摘要翻译：本发明提供了复合蛋白，包括显示出降低的免疫原性的抗体。特别地，提供了用于人的复合抗体，特别是已被修饰以除去一个或多个T细胞表位的抗体。还提供了产生这种蛋白质的方法。

6. 发明申请

WO2008044032A2 T CELL EPITOPE DATABASES 审中-公开
标题翻译： T细胞EPITOPE DATABASES
公开(公告)号：WO2008044032A2
公开(公告)日：2008-04-17
申请号：PCT/GB2007/003868
申请日：2007-10-11
申请人： ANTITOPE LIMITED , CARR, Frank , BAKER, Matthew, Paul
发明人： CARR, Frank , BAKER, Matthew, Paul
IPC分类号： G06F19/22 , G06F19/28
CPC分类号： G06F19/28 , G06F19/22
摘要： The invention relates to databases of T cell epitopes, especially helper T cell epitopes, for rapid interrogation of protein sequences for the presence of T cell epitopes. The invention includes full or partial databases and data structures of T cell epitopes including epitopes identified especially by ex vivo T cell assays with test peptides and includes T cell epitopes identified by extrapolation of data from test peptides. The present invention also includes high throughput methods for determining the T cell epitope activity of peptides for subsequent inclusion in databases and data structures including methods where subsets of T cells especially regulatory T cells are removed or inhibited from T cell assays in order to maximize the sensitivity of detection of T cell epitope activity.
摘要翻译：本发明涉及用于T细胞表位存在的蛋白质序列的快速询问的T细胞表位的数据库，特别是辅助T细胞表位。本发明包括T细胞表位的全部或部分数据库和数据结构，包括特异性通过具有测试肽的离体T细胞测定鉴定的表位，并且包括通过外推测试肽数据而鉴定的T细胞表位。本发明还包括用于确定肽的T细胞表位活性以用于随后包含在数据库和数据结构中的高通量方法，包括其中T细胞特别是调节性T细胞的亚群从T细胞测定中去除或抑制的方法，以使灵敏度最大化检测T细胞表位活性。

7. 发明申请

WO2006000448A2 Fc-INTERFERON-BETA FUSION PROTEINS 审中-公开
标题翻译： Fc-INTERFERON-BETA融合蛋白
公开(公告)号：WO2006000448A2
公开(公告)日：2006-01-05
申请号：PCT/EP2005/006925
申请日：2005-06-28
申请人： MERCK PATENT GMBH , GILLIES, Stephen, D. , WATKINS, Nigel, John , BAKER, Matthew, Paul , LO, King-Ming
发明人： GILLIES, Stephen, D. , WATKINS, Nigel, John , BAKER, Matthew, Paul , LO, King-Ming
IPC分类号： C07K14/555
CPC分类号： C07K16/46 , A61K38/00 , A61K47/48423 , A61K47/6813 , C07K14/565 , C07K2319/30
摘要： Disclosed are Fc-interferon-beta (Fc-IFN-β) fusion proteins and nucleic acid molecules encoding them. The Fc- IFN-β fusion proteins include variants of the interferon-beta (IFN-β) protein that are altered to achieve enhanced biological activity, prolonged circulating half-life and greater solubility. Also disclosed are methods of producing the fusion proteins and methods of using the fusion proteins and/or nucleic acid molecules for treating diseases and conditions alleviated by the administration of interferon-beta.
摘要翻译：披露了Fc-干扰素-β（Fc-IFN-β）融合蛋白和编码它们的核酸分子。 Fc-IFN-β融合蛋白包括干扰素-β（IFN-β）蛋白的变体，其被改变以实现增强的生物活性，延长的循环半衰期和更大的溶解度。还公开了产生融合蛋白的方法和使用融合蛋白和/或核酸分子治疗通过施用干扰素-β缓解的疾病和病症的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式